In the journey of cancer recovery, many patients and their families genuinely want to “do something” to help the body. However, not everything that seems healthy is actually suitable during cancer care.
Without proper medical supervision or data-driven personalization, well-intentioned habits can sometimes slow recovery, disrupt treatment, or even cause harm.
Because doing more doesn’t always mean doing what’s right
Cancer care is a deeply personal journey, yet many people walk this path relying only on standardized treatments or generic advice.
They take every supplement, follow every instruction, and still feel fatigued, emotionally drained, or slow to recover.
Why? Because effective cancer care is not about doing everything, but about doing the right things for your body—at the right time.
What Testing Can Reveal About Your Unique Health Needs
When we think of cancer care, most people immediately picture standard treatments: surgery, chemotherapy, radiation.
But growing clinical evidence shows that a one-size-fits-all approach is no longer enough.
Each cancer patient has a unique biological, genetic, and emotional profile—and that requires a different way of thinking.
This is why cancer care needs to be more personalized.
During periods of intense physical stress or ongoing medical care, many individuals experience persistent fatigue, reduced immunity, and a general sense of being unwell.
These symptoms are often linked to increased oxidative stress, immune system demands, and cellular repair needs.
One clinically supported supportive option that has gained increasing attention is High-Dose Intravenous Vitamin C (IVC) Therapy.
Each year, more than 20 million people worldwide are diagnosed with cancer — and increasingly, they are not just older adults. According to projections from the World Health Organization (WHO), global cancer cases may rise to nearly 30 million annually by 2040 if no active measures are taken.
This isn’t just a distant statistic — it’s a call to action.
And here’s the good news: Studies now suggest that up to 40% of cancers are preventable, especially when we intervene early with the right strategies.
At BMS, we believe that true prevention starts with the right knowledge, the right tools, and the right timing.
When we talk about cancer care, the focus often centers on active treatments like surgery, chemotherapy, or targeted therapies. However, supportive care strategies also play a critical role in helping the body recover, maintain stability, and rebuild its strength. Among these strategies, intravenous nutritional immunoglobulin therapy (IVIG) is emerging as a promising and gentle option for additional support.
In cancer care, most of the focus is placed on tumor markers, imaging results, or responses to treatment. Yet one often-overlooked blood marker—albumin—can quietly reflect a patient’s overall condition, prognosis, and even survival.
Though seemingly simple, this protein tells a deeper story about the body’s nutritional status, inflammation levels, and recovery capacity.
How BMS Supports Recovery Through Our Neurocognitive Health Program
When people hear the word cancer, they often think of tumors, genetic mutations, and clinical treatments like surgery, radiation, or chemotherapy. But in reality, cancer affects far more than just the physical body — it also places immense strain on the brain and emotional systems.
The wellness market is saturated with supplements—from vitamin C and D to herbal extracts and antioxidant blends.
Faced with overwhelming options, many people find themselves asking:
• “Do I really need to take all of these?”
• “Which one should I choose, and how much is enough?”
• “Are these supplements actually working for me?”
These questions point to the core issue:
Most people are making decisions about supplementation based on guesswork rather than science.
But in reality, nutritional support should be personalized, targeted, and data-driven.
This is where the RGCC Onconomics Plus test becomes a game-changer.
When we talk about early cancer detection, most people think of imaging tests or tumor markers.
These tools are valuable for identifying structural abnormalities or elevated markers — in other words, when a disease has already begun to manifest.
But what if you could go one step earlier?
Before anything is visible or measurable, is there a way to understand your underlying genetic risk?